Amoxicillin-clavulanate was no more effective than placebo in quickly relieving symptoms in patients diagnosed clinically with acute sinusitis in a general practice setting. It was, however, much more likely to cause diarrhea. Because most patients will improve spontaneously, antibiotics should be reserved for patients with prolonged symptoms. An inexpensive, narrow-spectrum drug such as amoxicillin is a good initial choice.
Q&A
Amoxicillin-clavulanate ineffective for suspected acute sinusitis
J Fam Pract. 2003 December;52(12):919-941
Author and Disclosure Information
Practice Recommendations from Key Studies
Bucher HC, Tschudi P, Young J, et al. Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice. Arch Intern Med 2003; 163:1793–1798.
Eric A. Jackson, PharmD
Department of Family Medicine, University of Connecticut School of Medicine and Saint Francis Hospital and Medical Center, Hartford. E-mail: ejackson2@stfranciscare.org.
- BACKGROUND: Fifty percent of patients with acute sinusitis will have a viral infection and will not benefit from antibiotic therapy. This study evaluated the effect of a broad-spectrum antibiotic on adults with acute sinusitis diagnosed clinically in general practice.
- POPULATION STUDIED: The investigators enrolled 252 adult patients over 4 winter seasons, recruited from general practices and the internal medicine and otolaryngology outpatient clinics of a university hospital in Basel, Switzerland. Clinical diagnosis was based on a history of repeated purulent nasal discharge and maxillary or frontal sinus pain for at least 48 hours but less than 1 month. Presence of pus under rhinoscopy was an initial inclusion criterion, but was dropped after the first winter season. After randomization, treatment groups were relatively well-matched for characteristics that would affect the outcomes of interest.
- STUDY DESIGN AND VALIDITY: Eligible patients were consecutively enrolled and randomly assigned (with concealed allocation) to receive amoxicillin 875 mg/clavulanic acid 125 mg or matching placebo twice daily for 6 days. Patients also received a topical nasal decongestant and acetaminophen, and were allowed to use steam inhalation. Central randomization was stratified by treatment site in blocks of 6.
- OUTCOMES MEASURED: The primary outcome was time to cure, defined as no days since the previous visit or interview during which symptoms restricted activity at home or work. Because 10% of recruited patients reported no restriction on activities, analysis of time to cure was repeated using a 10-point visual analog scale to describe degree of restriction on activity. Secondary outcomes included number of days during which symptoms restricted activity and frequency of adverse effects of antibiotics.
- RESULTS: Using either definition of cure, there was no difference in the primary outcome (time to cure) between treatment groups. Cure rates for amoxicillin-clavulanate and placebo at 1 week (29.8% and 30.7%) and 2 weeks (76.6% and 74.0%) were similar for the 2 groups. The time to cure was also similar between antibiotic-treated and placebo-treated patients. There was no significant difference between the 2 treatment groups in the secondary outcome of number of days of restricted activity. However, at 1 week patients who took amoxicillin-clavulanate were almost 4 times more likely to have diarrhea (odds ratio=3.89; 95% confidence interval, 2.09–7.25).
PRACTICE RECOMMENDATIONS